INTRODUCTION
The novel coronavirus infection (COVID-19) was prevalent in Wuhan since December 2019, including pregnant women1. In Wuhan, these patients represented 0.24% of all reported cases with COVID-192. COVID-19 affects the entire pregnancy; however, current research is mostly about pregnancy during the third trimester and peripartum2-4. In New York, of the 215 women screened for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on admission using nasopharyngeal swabs, 33 women (15.4%) were found positive. Of these positive cases, four had fever or other symptoms of COVID-19, while 29 were asymptomatic3.
Currently, there are a few reports on the outcome of COVID-19 in pregnant women during the first and second trimester, as well post-recovery. The effect of COVID-19 on pregnancy remains unclear, which obstetricians and neonatologists. Recent researches indicated that there is no clear evidence of intrauterine infection in pregnancy with COVID-19 during the third trimester2,5. However, both SARS-CoV-2 IgM and IgG were detected in newborns of infected mothers, which question the possibility of intrauterine infection6,7. Some studies claimed that a positive IgM test result could not be regarded as the definite evidence of vertical transmission8. Our previous study reported the clinical characteristics and placental pathological analysis of three peripartum women with COVID-199. We noted no severe adverse pregnancy outcomes or morphological changes related to infection. All samples were negative for the SARS-CoV-2 nucleic acid9. We concluded that COVID-19 intrauterine infection does not occur during the third trimester.
The aim of our current study is to determine the safety and postpartum outcomes in pregnant patients infected from early pregnancy (first and/or second trimester) with COVID-19.